SEARCH:   Advanced

Blood, 15 April 2008, Vol. 111, No. 8, pp. 3986-3990. Prepublished online as a Blood First Edition Paper on January 2, 2008; DOI 10.1182/blood-2007-10-115659. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-10-115659v1 111/8/3986    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bower, M. Articles by Powles, T. Search for Related Content PubMed PubMed Citation Articles by Bower, M. Articles by Powles, T. Related Collections Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma Mark Bower1, Justin Stebbing1, Mark Tuthill1, Victoria Campbell1, Johnathan Krell1, Paul Holmes2, Andrew Ozzard1, Mark Nelson2, Brian Gazzard2, and Tom Powles3 Departments of1 Oncology and 2 HIV Medicine, Imperial College School of Medicine, London; and 3 Department of Oncology, St Bartholomew's Hospital, London, United Kingdom The late effects of chemotherapy on immunologic parameters in AIDS-related non-Hodgkin lymphoma (NHL) have not been described. From a cohort of 105 consecutive patients treated with infusional chemotherapy and highly active antiretroviral therapy (HAART), 68 survived more than 3 months following the end of chemotherapy. Their lymphocyte subsets and plasma HIV viral loads were measured at regular intervals for 2 years and values compared with baseline. During chemotherapy, there were statistically significant falls in CD4 (helper T), CD8 (cytotoxic T), and CD19 (B) cell populations but no changes in the CD56 (natural killer [NK]) cell population. Among the 68 survivors, there were statistically significant increases in CD4, CD8, CD19, and CD56 cell populations during the first year of follow up, compared with the values at the start of chemotherapy. During the second year of follow up, there were further statistically significant rises in CD4 and CD19 cell populations, compared with the values at 12 months after chemotherapy. During 244 years of follow-up since chemotherapy in these 68 survivors, 7 second primary tumors and 8 opportunistic infections were diagnosed. Chemotherapy and concomitant HAART for AIDS-related NHL does not cause prolonged suppression of lymphocyte subsets. These data should provide reassurance regarding the long-term consequences of chemotherapy in these individuals. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: AIDS, T cells, chemotherapy: HAART-breaking? Richard F. Little Blood 2008 111: 3921-3922. [Full Text] [PDF] This article has been cited by other articles: L. Lin, J. Y. Lee, L. D. Kaplan, B. J. Dezube, A. Noy, S. E. Krown, A. M. Levine, Y. Yu, G. S. Hayward, and R. F. Ambinder Effects of Chemotherapy in AIDS-Associated Non-Hodgkin's Lymphoma on Kaposi's Sarcoma Herpesvirus DNA in Blood J. Clin. Oncol., May 20, 2009; 27(15): 2496 - 2502. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020